This book follows on from the previous two books in the series, which have been of great value to Doctors, Pharmacists, and Patients. Written by experienced LDN Specialists with a wealth of experience, they share case studies and endless references to clinical trials and published papers. Included in the book: Pharmacology and Best Clinical Practices, Dosing Protocols, Drug-Resistant Depression, Virally Damaged Tissues (COVID-19, Herpes Simplex (HSV 1 & 2), Varicella-Zoster, Human Parvovirus B19 (B19V), Epstein-Barr (EBV), Longevity, Mixed Connective Tissue Disease, Mold Illness and CIRS, Ophthalmic Conditions, Long COVID and Cancer.

A comprehensive examination of Low Dose Naltrexone – a little-known drug with big potential New drug [LDN] raises hopes of reversing memory loss in old age the Guardian A drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination. Expanding on the information presented in The LDN Book, Volume 1 – which showcased LDN’s efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue – Volume 2 highlights the latest clinical trials, case studies and research on LDN. More than a dozen medical professionals explain how they are using LDN to help patients suffering from: Chronic pain Parkinson’s disease Dermatologic conditions Traumatic brain injury  Lyme disease and more. Volume 1 and Volume 2 have been edited by Linda Elsegood, founder of the UK-based LDN Research Trust. Through the Trust and her work on the LDN books, Linda has connected thousands of patients, doctors and pharmacists around the world with information, articles and patient stories about LDN. The LDN Book, Volume 2 is a fantastic resource for practitioners, pharmacists and patients and a renewed call for further research on the healing potential of this beneficial drug.

Low Dose Naltrexone (LDN) holds the potential to help millions of people suffering from various autoimmune diseases and cancers, and even autism, chronic fatigue, and depression, find relief. Administered off-label in small daily doses (0.5 to 4.5 mg), this generic drug is extremely affordable and presents few known side effects. So why has it languished in relative medical obscurity? The LDN Book explains the drug's origins, its primary mechanism, and the latest research from practicing physicians and pharmacists as compiled by Linda Elsegood of The LDN Research Trust, the world's largest LDN charity organization with over 19,000 members worldwide. Featuring ten chapters contributed by medical professionals on LDN's efficacy and two patient-friendly appendices, The LDN Book is a comprehensive resource for doctors, pharmacists, and patients who want to learn more about how LDN is helping people now, and a clarion call for further research that could help millions more.